Gaithersburg, MD’s Altimmune has secured a sizable contract with BARDA to further develop its nasal spray anthrax vaccine candidate, building on an existing collaboration as the biotech prepares to move into clinical trials.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares of Aptevo common stock to the holders of Emergent BioSolutions common stock. As a result of the spin-off, Aptevo is now an independent public company and listed on the Nasdaq Global Select Market under the ticker symbol “APVO.”
GlaxoSmithKline and Alphabet unit Verily (formerly Google Life Sciences) made a splash yesterday when they announced the launch of Galvani Bioelectronics, a company that will build upon GSK’s three years of work to develop tiny nerve-altering devices that might one day be used instead of drugs to treat a variety of diseases. The two companies will invest up to £540 million (more than $700 million) over the next seven years, they said, employing 30 scientists at GSK’s research center in the U.K. and at Verily in South San Francisco.
Yes, Hollywood may dramatize the plight of the entrepreneur. But sometimes the best way to capture reality is through fiction. Wherever you are in your business venture, you can glean some insight from these 18 provocative and wildly entertaining films.
We are delighted to announce Illumina Accelerator is accepting applications for its next funding cycle in San Francisco. Illumina Accelerator is the world’s first business accelerator focused on creating an innovation ecosystem for the genomics industry. It drives value for genomics startups developing breakthrough applications in therapeutics, diagnostics, agriculture, direct to consumer, synthetic biology, and beyond. Selected genomics startups will receive seed investment, business guidance, and fully operational lab space for six months in San Francisco, starting in January 2017. Applications for the fifth funding cycle are due by September 1, 2016.
The House Small Business Committee issued a report (H.Rpt. 114-705) on legislation (H.R. 4783) to reauthorize and improve the Small Business Innovation Research Program…
To address one of the greatest modern threats to public health — antibiotic resistance — the U.S. Department of Health and Human Services (HHS), the Wellcome Trust of London, the AMR Centre of Alderley Park (Cheshire, United Kingdom), and Boston University School of Law will create one of the world’s largest public-private partnerships focused on preclinical discovery and development of new antimicrobial products.
GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.
Today, University of Maryland (UM) Ventures announced the appointment of Darryl L. Carter, MD, co-founder and former vice president of Nora Therapeutics, Inc., as Venture Advisor at the University of Maryland Baltimore’s (UMB) Office of Technology Transfer (OTT). In this role, Dr. Carter, who previously supported UMB’s OTT and entrepreneurially focused inventors as an entrepreneur-in-residence, will assist faculty in turning their technology inventions into commercial opportunities. Dr. Carter will also help support the formation of new UMB technology-based start-up companies.
Zika has been in the spotlight lately with summer in full swing and the Olympics in Rio just around the corner. A company in Montgomery County is working on a vaccine that could save lives.
Emergent Biosolutions was awarded a contract by the U.S. government worth nearly $22 million. Scientists will begin working on the vaccine within just a few days.